This week, Steve and I have put together a great summary of the top stories from the European Association for the Study of Diabetes Conference in Salzburg, Austria. Although there was a lot of great news, the bottom line was not much...
|
Quote #489
|
"Without a sense of caring, there can be no sense of community."
..................Anthony J. D’Angelo...
|
Test Your Knowledge #489
|
A 25-year-old man who has had Type 1 diabetes for 10 years is evaluated for increased frequency of hypoglycemia and fatigue. Hypoglycemic episodes have particularly occurred during the late afternoon and night.
|
If Mom Works, Kids' Lifestyle Less Healthy
|
If Mom Works, Kids' Lifestyle Less Healthy: Children of working mothers may be less likely to lead a healthy lifestyle, researchers said. British kids whose mothers worked part- or full-time were...
|
Researchers Unlock the Secret to Aging
|
Researchers Unlock the Secret to Aging. A team of researchers has discovered they can extend the lives of mice by genetic manipulation, which mimics the health benefits of a low-calorie diet. Researchers have known...
|
Metformin Could Extend Lives 15 Years
|
Metformin Could Extend Lives 15 Years. A drug used to treat diabetes could help people add up to 15 years to their life expectancy, claim scientists. British researchers believe that metformin used to treat Type 2 diabetes could also extend...
|
EASD: Lidocaine Patch Beats Pregabalin for Diabetic Nerve Pain
|
A dermal patch containing 5% lidocaine (Lidoderm) proved as effective as pregabalin (Lyrica) in relieving neuropathic pain in diabetic patients with dramatically fewer side effects.
|
EASD: New First in Class Drug Effective in Phase III Trial
|
An investigational drug targeting an insulin-independent pathway in Type 2 diabetes produced early and substantial reductions in blood glucose and body weight in a phase III study.
|
EASD: Link Between Severe Mental Illness, CVD, Diabetes
|
European organizations are calling for improved care and screening for CVD and diabetes in those with mental illnesses.
|
EASD: Superior Efficacy-Dose Ratio for Lantus® over Detemir
|
Seventy-six percent higher dose of insulin detemir needed to achieve similar, well tolerated glycemic control versus Lantus®.
|
EASD: Early Treatment of Gestational Diabetes Reduces Risk 50% for Complications
|
Researchers are reporting that treatment of even the mildest forms of gestational diabetes halves the risk of delivering newborns with excess body fat and shoulder dystocia at birth. Treatment also results in fewer cesarean deliveries and...
|
EASD: Metformin Protects against Cancer in Type 2 Diabetes
|
Metformin was found to reduce risk in pancreatic and colon cancers in patients with Type 2 diabetes in an epidemiologic study.
|
EASD: AFRESA® Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function in Patients over Four Years of Treatment
|
Long-term study in adults with Type 2 diabetes presented at the 45th annual meeting of the European Association for the Study of Diabetes.
|
EASD: Insulin Analogues, Cancer Linked, but No Causality Shown
|
Patients taking insulin-based drugs for diabetes appear prone to increased rates of cancer diagnosis, but there appears to be no special risk for insulin glargine (Lantus) compared with other insulins, researchers said.
|
EASD: XOMA Presents Novel Mechanism of Action for XOMA 052 in Regulating IL-1 Beta Levels
|
XOMA, a leader in the discovery and development of therapeutic antibodies, announced new data demonstrating the unique regulatory mechanism of action of XOMA 052, a potent antibody drug candidate that inhibits the inflammatory...
|
| | | | | | | | | | | | |